دورية أكاديمية
Cohort event monitoring of patients treated for uncomplicated malaria with artemisinin-based combination therapies in selected hospitals and community pharmacies in Nigeria
| العنوان: | Cohort event monitoring of patients treated for uncomplicated malaria with artemisinin-based combination therapies in selected hospitals and community pharmacies in Nigeria |
|---|---|
| المؤلفون: | P U Bassi, A I Osakwe, C Suku, M Kalat, C Elagbaje, A Isah, S Ayinbuomwan, R D Wammanda, I I Bob-Okon, J Ambe, Y Mava, A O Adesina, C G Ugochukwu, E E Nyong, O O Ogunleye, F Onuoha, I Jalo, V O Adegoke, S T Balogun, G Ntadom, F N Ejiekpe, R Tahir, K Dabit, A A Amodu, S Nwaosu, A T Habib |
| المصدر: | Nigerian Postgraduate Medical Journal, Vol 23, Iss 4, Pp 172-181 (2016) |
| بيانات النشر: | Wolters Kluwer Medknow Publications, 2016. |
| سنة النشر: | 2016 |
| المجموعة: | LCC:Medicine |
| مصطلحات موضوعية: | artemisinin combination therapies, cohort event monitoring, uncomplicated malaria - nigerians, Medicine |
| الوصف: | Aims and Objectives: The study was designed with the broad objective of determining the safety profile of artemisinin-based combination therapies amongst Nigerian population. Patients and Methods: This was a cohort event monitoring (CEM) programme involving monitoring adverse events (AEs) in malaria patients treated with either artemether-lumefantrine (AL) or artesunate-amodiaquine (AA) in healthcare facilities in Nigeria. The study involved continuous enrolment of patients with malaria and treated with either AL or AA at the various sites until a total cohort of 600 patients were enrolled at each site. Patients were monitored from the onset of therapy, and on days 3 and 7 from the first day of treatment to identify AEs that may occur. Results: A total of 6102 AEs were recorded in 10,259 patients monitored during the programme. Of 4896 patients who received AA, 4233 (86.5%) patients reported at least one AE while 1869 (34.8%) AEs out of 5363 patients who received AL were reported (P = 0.010). The predominant incidence of each specific AE reported in each group among the patients who received AA and AL includes body weakness 30.8%/7.5%, dizziness 10.3%/3.9%, restlessness 5.02/1.12%, vomiting 3.5/1.03% and drowsiness 3.1/1.5% for AA and AL, respectively. There were more AEs among patients with co-morbid conditions and patients in the younger age groups (9- |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1117-1936 2468-6875 |
| العلاقة: | http://www.npmj.org/article.asp?issn=1117-1936;year=2016;volume=23;issue=4;spage=172;epage=181;aulast=BassiTest; https://doaj.org/toc/1117-1936Test; https://doaj.org/toc/2468-6875Test |
| DOI: | 10.4103/1117-1936.196246 |
| الوصول الحر: | https://doaj.org/article/b08467223f46496abf7f47839c8748e6Test |
| رقم الانضمام: | edsdoj.b08467223f46496abf7f47839c8748e6 |
| قاعدة البيانات: | Directory of Open Access Journals |
| تدمد: | 11171936 24686875 |
|---|---|
| DOI: | 10.4103/1117-1936.196246 |